Chris Calabrese | LifeSci Advisors, LLC |
Alexander Sapir | President and Chief Executive Officer |
Iain Fraser | Interim Chief Medical Officer |
Gregory Tourangeau | Principal Accounting Officer |
Benazir Ali | Stifel |
Joseph Schwartz | Leerink Partners |
Edward Tenthoff | Piper Sandler |
Matthew Hagood | Oppenheimer |
Judah Frommer | Credit Suisse |
Good morning and welcome to the Fulcrum Therapeutics Second Quarter 2023 Financial Results and Business Update Conference Call. Currently all participants are in a listen-only mode. This call is being webcast live on the Investor Section of Fulcrum’s website at www.fulcrumtx.com and is being recorded.
Please be reminded that remarks made during this call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These may include statements about the company's future expectations and plans, including the clinical hold on FTX-6058, clinical development time lines and financial projections.